Biofrontera AG
Biofrontera Initiates U.S. Commercial Launch of Ameluz® for Actinic Keratosis - Seite 2
"The commercial launch of Ameluz® in the U.S. represents a major milestone for Biofrontera, and we are pleased with the initial feedback from our experienced sales force," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "We are well prepared to serve the rapidly growing PDT market as indicated by the accelerated activity at our production facility for the accompanying BF-RhodoLED® lamps, many of which are in the process of being installed in dermatology offices across the U.S. Additionally we will host a VIP event at the Fall Clinical Dermatology Conference in Las Vegas later this week, to broadly announce the launch of Ameluz® to the US dermatology community."
In addition to the United States, Ameluz® is commercially available in 13 countries throughout the European Union, which recently expanded the label for Ameluz® to include field cancerization and the skin rejuvenation data.
The Fall Clinical Dermatology Conference is an annual meeting organized by the American Association of Dermatology (AAD). It is the second largest annual conference for US dermatologists and takes place in Las Vegas from October 20th to 23rd, 2016.
Enquiries, please contact: Biofrontera AG
Anke zur Mühlen, IR
+49 (0) 214 87 63 2 0
press@biofrontera.com
IR Germany: Brainwell Asset Solutions
Jürgen Benker
+49 (0) 152 08931514
IR UK: Seton Services
Toni Vallen
+44(0) 20 7229 0805
IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
+1 646-536-7012 / 7035
PR: Kirsten Thomas
+1 508-280-6592
Lesen Sie auch
Background:
Biofrontera Group (FSE: B8F, ISIN DE0006046113) Biofrontera is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the US
for the treatment of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up
company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.